Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Omid Veiseh email address & phone number Avenge Bio Co-Founder contact information - RocketReach

Bio Tech Nutra Avenger - Stack3d Database

MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk

How far would YOU go to avenge a friend? 😈 Details on this insane story at link in bio, link in Stories, or go here:…

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

BioCentury - Asif Ali to join Protagonist as CFO

Commercialization Highlights, Office of Technology Transfer, Office of Research

Avenge Bio Closes $45 Million Series A Financing

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…

New pinhead-sized beads kill ovarian, colorectal cancers by producing interleukin-2: mouse study

Avenge Bio on LinkedIn: Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian…

DelveInsight Business Research LLP on LinkedIn: Pharma News Updates for AbbVie, Novartis, Avenge Bio, Eli Lilly

Biotech, Pharmaceutical and Clinical Research News

Avenge Bio to Begin Clinical trials of Immunotherapy Technology, Department of Bioengineering

BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial